The effect of acyl CoA: cholesterol acyltransferase inhibition on the uptake, esterification and secretion of cholesterol by the hamster small intestine

RE Burrier, AA Smith, DG McGregor, LM Hoos, DL Zilli and HR Davis

Department of Cardiovascular Pharmacology, Schering-Plough Research Institute, Kenilworth, New Jersey.

Acyl CoA: cholesterol acyltransferase (ACAT) inhibitors are known to inhibit cholesterol absorption and are under investigation to reduce hypercholesterolemia. These studies examine the effect of an ACAT inhibitor 2,2-dimethyl-N-(2,4,6-trimethoxyphenyl)-dodecanamide (PD128042) on the uptake, metabolism and secretion of cholesterol by the hamster intestinal wall in a short-term model. Preliminary studies in this model indicated that the uptake of 14C-cholesterol and its subsequent esterification 2 hr postoral dosing occurs primarily in the duodenal and jejunal segments of the small intestine and most of the radiolabeled cholesterol and cholesteryl ester in the plasma was associated with chylomicrons. In both single- and multiple-dose studies, PD128042 (50 mg kg-1 day-1) did not inhibit intestinal uptake of [14C]-cholesterol but [14C]-cholesteryl ester formation was inhibited. The free [14C]-cholesterol appearing in plasma was not affected despite a large reduction in [14C]-cholesteryl ester. In contrast, cholestyramine (1 g kg-1 day-1) inhibited the uptake of the radiolabeled free cholesterol and the appearance of cholesteryl ester in the intestine and plasma. The effects of PD128042 on cholesterol and cholesteryl ester mass associated with scraped intestinal mucosa were consistent with the effects observed with the use of the radiolabeled cholesterol. In addition, PD128042 did not affect the uptake of appearance of radiolabeled triglyceride in the intestinal wall after oral gavage of 3H-trioleoylglycerol. Taken together, the data suggest that ACAT inhibition reduces cholesterol absorption by limiting cholesteryl ester incorporation into chylomicrons and has no effect on the intestinal processing of free cholesterol to be secreted into plasma.

Volume 272, Issue 1, pp. 156-163, 01/01/1995
Copyright © 1995 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				H. R. Davis Jr, L. M. Hoos, G. Tetzloff, M. Maguire, L.-j. Zhu, M. P. Graziano, and S. W. Altmann Deficiency of Niemann-Pick C1 Like 1 Prevents Atherosclerosis in ApoE-/- Mice Arterioscler. Thromb. Vasc. Biol., April 1, 2007; 27(4): 841 - 849. [Abstract] [Full Text] [PDF]

				T J Kowalski, B D Spar, L Markowitz, M Maguire, A Golovko, S Yang, C Farley, J A Cook, G Tetzloff, L Hoos, et al. Transgenic overexpression of neuromedin U promotes leanness and hypophagia in mice J. Endocrinol., April 1, 2005; 185(1): 151 - 164. [Abstract] [Full Text] [PDF]

				H. R. Davis Jr, D. S. Compton, L. Hoos, and G. Tetzloff Ezetimibe, a Potent Cholesterol Absorption Inhibitor, Inhibits the Development of Atherosclerosis in ApoE Knockout Mice Arterioscler. Thromb. Vasc. Biol., December 1, 2001; 21(12): 2032 - 2038. [Abstract] [Full Text] [PDF]

				M. van Heek, T. M. Austin, C. Farley, J. A. Cook, G. G. Tetzloff, and H. R. Davis Ezetimibe, a Potent Cholesterol Absorption Inhibitor, Normalizes Combined Dyslipidemia in Obese Hyperinsulinemic Hamsters Diabetes, June 1, 2001; 50(6): 1330 - 1335. [Abstract] [Full Text]

				I.J. Martins, B.-C. Mortimer, and T.G. Redgrave Effect of the ACAT Inhibitor CL 277,082 on Apolipoprotein B48 Transport in Mesenteric Lymph and on Plasma Clearance of Chylomicrons and Remnants Arterioscler. Thromb. Vasc. Biol., January 1, 1997; 17(1): 211 - 216. [Abstract] [Full Text]

				P. J. Uelmen, K. Oka, M. Sullivan, C. C. Y. Chang, T. Y. Chang, and L. Chan Tissue-specific Expression and Cholesterol Regulation of Acylcoenzyme A:Cholesterol Acyltransferase (ACAT) in Mice J. Biol. Chem., November 3, 1995; 270(44): 26192 - 26201. [Abstract] [Full Text] [PDF]